Munich-based mk2 Biotechnologies today announced the receipt of several million Euros in seed funding to accelerate the further growth of the company. In particular, the company thrives to accomplish additional development milestones towards industrializing its novel peptide production platform. The financing round was led by OCCIDENT, with significant funds also [...]
We are happy to announce that we have been selected to participate in the MassChallenge Switzerland 2020 accelerator program. mk2 Biotechnologies was one of over 1.000 other startups to apply for the accelerator located in Lausanne, Switzerland. Looking very forward to engaging with industry experts, corporates, investors and a global [...]
mk2 Biotechnologies is presented in this month's CheManager Innovation Pitch - read more on our long way from lab to fab here.